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This was a rapid review of systematic reviews (SRs) on problematic polypharmacy
(PP) in the UK. The commissioner-defined topics were burden of PP, interventions
to reduce PP, implementation activities to increase uptake of interventions, and
efficient handover between primary and secondary care to reduce PP.
Databases including Medline were searched to June 2019, SR quality was assessed
using AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews) and a narrative
synthesis was undertaken.
Except for burden of PP (SRs had to include UK studies), there were no restrictions
on country, location of care or outcomes.
Nine SRs were included. On burden, three SRs (including six UK studies) found a high
prevalence of polypharmacy in long term care. PP was associated with mortality,
although unclear if causal, with no information on costs or health consequences.
On interventions, six reviews (27 UK studies) found that interventions can reduce
PP, but no effects on health outcomes. On handover between primary and secondary
care, one review (two UK studies) found medicine reconciliation activities to reduce
medication discrepancies at care transitions reduce PP, although the evidence is low
quality. No SRs on implementation activities to increase uptake of interventions
were found.
SR quality was variable, with some concerns regarding meta-analysis methods.
Evidence of the extent of PP in the UK, and what interventions to address it are
effective in the UK, is limited. Future UK research is needed on the prevalence and
consequences of PP, the effectiveness and cost-effectiveness of interventions to
reduce PP, and barriers and activities to ensure uptake.
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1 | INTRODUCTION
Medicines use is increasing in the UK as well as internationally.1
In England, from 2012/13 to 2015/16, the proportion of people
prescribed 5-7 medicines increased by 8% and, in those on 8 or more
medicines, by 3%.2 Extrapolating to the population, this amounts
to 4.8 million people on 5-7 medicines and 2.8 million people
on 8 or more medicines. Much of this multiple medicine use
(ie, polypharmacy) may be appropriate, but some patients may be
exposed to problematic polypharmacy, also known as overprescribing.
Problematic polypharmacy refers to the use of multiple medicines
inappropriately or without the intended benefit.3 Examples include
contraindicated drugs, potential for drug interactions or prescribing a
drug that has caused adverse drug reactions in the past.3
Problematic polypharmacy is a key area of concern for the
NHS and UK policy makers. For example, to address problematic
polypharmacy, NHS England announced in 2019 that it is recruiting
200 clinical pharmacists to work in care homes and plans to increase
the number of clinical pharmacists working in primary care over the
coming years.4
In 2018, the UK Secretary of State for Health commissioned the
Short Life Working Group (SLWG) on Overprescribing to conduct a
Review.5 The SLWG Review will consider problematic polypharmacy,
handover between primary and secondary care, management of
repeat prescriptions, digital technologies and social prescribing. Social
prescribing is a term used in the UK for a referral to a link worker. The
link worker helps people to improve their wellbeing (rather than
focusing only on their health) by connecting them to community
groups and services.6 To inform this Review, the Department of
Health and Social Care (DHSC) commissioned the present study to
summarise the evidence on problematic polypharmacy and propose
areas for future research.
The a priori defined topics and associated research questions for
the present study, agreed between the DHSC and the Short Life
Working Group on Overprescribing, were:
• Burden of problematic polypharmacy: What is the prevalence
(and/or incidence), what are the costs to the NHS and what
are the health consequences of polypharmacy and problematic
polypharmacy in the UK?
• Interventions to reduce problematic polypharmacy: What is the
effectiveness of interventions to reduce problematic polypharmacy,
with specific focus on deprescribing guidelines, routine data and
digital technologies?
• Implementation activities to increase uptake of interventions to
reduce problematic polypharmacy: What is the effectiveness of
implementation activities to increase the uptake of interventions
that reduce problematic polypharmacy, with specific focus on
activities to increase shared decision making?
• Efficient handover between primary and secondary care to reduce
problematic polypharmacy: What is the effectiveness of medicine
reconciliation interventions to reduce discrepancies in medication
in people at risk of problematic polypharmacy?
2 | METHODS
2.1 | Overview
Given the wide range of commissioned topics and questions, and the
two-month timeframe to present the findings to the DHSC, a rapid
review of existing systematic reviews in problematic polypharmacy
was undertaken. The study was undertaken in accordance with
the current Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines.7 The protocol for the rapid
review is registered with PROSPERO (CRD42019141295).
2.2 | Searches
MEDLINE (via Ovid), Embase (via Ovid) and Cochrane Database of
Systematic reviews (via Wiley) were searched to June 2019 to identify
systematic reviews on problematic polypharmacy. The search was
limited to systematic reviews, in English, published in the last 10 years
and in people aged 65 years and over. The search did not look for
evidence on specific activities/interventions given that none were
pre-specified by the SLWG. A copying of the MEDLINE search
strategy is presented in Appendix 1.
2.3 | Inclusion and exclusion criteria
Systematic reviews were included if they were full-text, peer-reviewed
publications that evaluated any of the four topics (burden of problematic
polypharmacy, interventions to reduce problematic polypharmacy,
implementation activities to increase uptake of interventions to reduce
What is already known about this subject
• Problematic polypharmacy is a concern for UK health
policy.
• In 2018, the UK Secretary of State for Health
commissioned a review into overprescribing in the NHS,
including problematic polypharmacy.
• This study informs this review by summarising the
existing evidence on problematic polypharmacy and
proposing areas for future research.
What this study adds
• Existing systematic reviews include few UK studies on
problematic polypharmacy.
• They provide very little information on the extent of
problematic polypharmacy and what interventions to
address it are effective in the UK.
• Problematic polypharmacy in the UK is now an area
requiring further research to help inform UK health policy.
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problematic polypharmacy, and efficient handover between primary
and secondary) and associated research questions for this rapid review.
The burden of problematic polypharmacy was defined as consequences
on health (measured with any health outcome measures, but with
specific attention to health-related quality of life and mortality), resource
use or costs.
Problematic polypharmacy was defined in accordance with the
definition provided by the King's Fund as “prescribing of multiple
medications inappropriately, or where the intended benefit of the
medication is not realised”.3 Where no systematic review using this
definition was available for a specific research question, other
systematic reviews were eligible for inclusion as long as their focus
was on problematic polypharmacy.
Only systematic reviews that were awarded a “yes” on four of the
AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews) quality
checklist criteria8 were included, as follows: the search strategies
were comprehensive, data extraction was performed in duplicate, a
satisfactory technique was used to assess study quality, and the
included studies were described in adequate detail. We considered
these criteria important in the context of the reproducibility of the
review, the accuracy of the data it contains, interpretation of the quality
of the evidence included and the transparency of the review findings.
There were no restrictions on country, except to inform the
topic on burden of problematic polypharmacy (where reviews had to
include UK studies), no restrictions in the location of care and no
restrictions on outcomes.
2.4 | Study selection and data extraction
One reviewer screened the records to identify the included studies and
undertook the data extraction and quality assessment. A second
independent reviewer checked the extracted data (including the quality
assessment) against the publications for accuracy. Data that were
extracted included the review question, the patient population and/or
setting, the number of included studies and the number conducted in the
UK, interventions and comparators (where appropriate), outcomes and
information to inform the AMSTAR-2 assessment for this rapid review. A
copy of the extracted data from the included systematic reviews is
presented in Appendix 2. As this was a rapid review, details of the
included UK studies were extracted directly intoTable 1 (Appendix 3).
2.4.1 | Quality assessment
We assessed the methodological quality of included systematic
reviews using the AMSTAR-2 checklist.8
2.5 | Synthesis
A narrative evidence synthesis was undertaken. No meta-analysis
was planned. A GRADE (Grading of Recommendations Assessment,
Development and Evaluation) was not planned.
3 | RESULTS
3.1 | Study selection
The PRISMA flow diagram of the study selection process is presented
in Figure 1. Following deduplication, 481 unique records were
identified, 459 of which were excluded at the title/abstract screen.
Twenty-two potentially relevant full-text articles were obtained, 12 of
which were excluded. The table of the 12 articles excluded at the
full-text stage, with reason for exclusion, is presented in Appendix 3.
Of the 12 articles, five were excluded based on the quality assessment
criteria for inclusion in this rapid review. Details of the quality
assessment judgements for exclusion, along with the topic covered by
the excluded reviews, are also presented in Appendix 3. Nine
systematic reviews (across 10 publications) were included in this
rapid review.9,10,13,16,18,19,24,32,48,49
3.2 | Overview of included studies
All of the included systematic reviews were international, with most
including some UK studies. Table 1 summarises the systematic
reviews by topic, including the number of included studies, the
definition of polypharmacy for studies to be included, the number
of included studies conducted in the UK and the key findings of
each systematic review. Where UK studies were included in a
systematic review, a brief summary of each UK study is also
presented in Table 1. Studies were considered to be in the UK if
they were set in England and/or Wales and/or Scotland and/or
Northern Ireland (but not if the systematic review indicated the
study as being in Ireland).
None of the included systematic reviews reported using the
King's Fund definition of polypharmacy for included studies.3 Six of
the systematic reviews did not report any definition of polypharmacy
for included studies.13,16,18,19,24,32,48 Two systematic review defined
polypharmacy as ≥four medications,9,49 and one define polypharmacy
as ≥five medications.10
3.3 | Burden of problematic polypharmacy: Findings
Three systematic reviews were on the topic of the burden of
problematic polypharmacy.18,24,32 Jokanovic et al24 evaluated the
prevalence of, and the factors associated with, polypharmacy in
people living in long-term care facilities. The review included
44 studies, three of which were UK studies.11,12,14 Leelakanok et al32
undertook a systematic review and meta-analysis on the association
between polypharmacy and mortality risk in various populations
and settings. The review included 47 studies, two of which were in
the UK.38,39 Hill-Taylor et al18 (previous review to the 2016 update18)
evaluated the prevalence of potentially inappropriate prescribing
(PIP) in older adults and the effectiveness of the application of
the Screening Tool of Older Persons' potentially inappropriate
prescriptions/Screening Tool to Alert doctors to the Right Treatment
(STOPP/START). It included 13 studies, one of which was in the UK.15
MARTYN-ST JAMES ET AL. 3
TABLE 1 Summary of included systematic reviews and included UK studies
Study
Definition of polypharmacy
for included studies
Total number of
studies (UK) Included UK studies Key findings across all included studies
Topic: Burden of PP (six UK studies out of 104)
Jokanovic et al24 Not defined 44 (3) • Gadsby et al was a retrospective case notes review in 75
people with diabetes living in 11 long-term care facilities.
They found that 45.3% of patients were on 4-7 medicines,
24.7% on 8-11 medicines and 4% on 13+ medicines11
Honney et al was a cross-sectional study of 316 people living
in a long-term care facility who had an emergency hospital
admission. They found that 50.5% were on 4-7 medicines
and 42.1% were on 9+ medicines12
• Whitney et al was a prospective cohort study in 240
patients aged over 60 years and resident in 10 long-term
care facilities. They found that 69% were on 7+ medicines14
• Studies varied on the definition of polypharmacy
• Prevalence of polypharmacy varied by study
• Polypharmacy more likely with greater number of
comorbidities, recent hospital discharge and greater number
of prescribers
• Polypharmacy less likely with older age, cognitive
impairment, impairment in activities of daily living and
length of stay in long-term care facility
Leelakanok et al32 Not defined 47 (2) • Richardson et al was a prospective cohort study in England
and Wales comparing the outcomes of 1586 older people
on ≥5 medicines with 10 837 people on <5 medicines over
18 years of follow-up. The risk ratio for all-cause mortality
controlling for age and comorbidities was 1.30 (95% CI 1.19
to 1.42)14
• Shah et al was a retrospective cohort study using routine
healthcare records, comparing the outcomes of a
community cohort of 354 306 patients on 0-2 medicines
with those of an institutional cohort of 9772 patients on
6-10 medicines. The risk ratio for all-cause mortality, and
adjusting for age, sex, comorbidities and other
characteristics was 1.96 (95% CI 1.42 to 2.71)15
• Studies varied on the definition of polypharmacy
• Polypharmacy is associated with higher mortality risk
Hill-Taylor et al16 Not defined 13 (1) • Parsons et al conducted an observational cross-sectional
study which applied the partial STOPP criteria to 119
people living with dementia in long-term care facilities
whose mean age was 87 years. The mean number of
medicines was 8, 41-46% had ≥1 PIMs17
• The prevalence of PIMs varied between 21% and 79% and
the prevalence of PPO varied between 23% and 74%
• Higher prevalence of PIMs and PPOs was associated with
older age, female sex, polypharmacy and comorbidities
The direct cost of PIP (PIM or PPO) was estimated in three
studies at €263-€318 per patient per year (Northern Ireland
and Republic of Ireland); no further details were provided in
the systematic review
Topic: Interventions to reduce PP (27 UK studies out of 240)
Clyne et al8 Not defined 12 (0) • None in UK • Organisational interventions reduce PIP (N = 4 out of 6
RCTs)
• Evidence of the effectiveness of multidisciplinary teams was
weak
• Clinical decision support systems reduce new PIP but not
existing PIP (N = 2 RCTs)
• Multifaceted interventions reduce PIP (N = 3 out of 4 RCTs)
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TABLE 1 (Continued)
Study
Definition of polypharmacy
for included studies
Total number of
studies (UK) Included UK studies Key findings across all included studies
Hill-Taylor et al16,18 Not defined 15 (1) • Parsons et al conducted an observational cross-sectional
study which applied the partial STOPP criteria to 119
people living with dementia in long-term care facilities
whose mean age was 87 years. The mean number of
medicines was 8, 41-46% had ≥1 PIMs17
• 2013 review: There were some challenges in applying the
STOPP/START criteria (version not specified but likely
version 1)
• 2013 review: Six studies found the STOPP criteria more
sensitive than Beers to detect PIP
• 2016 review: Interventions increased the chances that PIMs
were reduced (random effects; OR 2.98; 95% CI 1.30, 6.93;
N = 4 RCTs; I-squared = 87.6%)
Johansson et al19 ≥4 medications 25 (4) • Lenaghan et al was an RCT comparing home-base
medication reviews by a pharmacist with usual care in 134
community-dwelling older people over 6 months'
follow-up.20 The primary outcome was number of
non-elective admissions (RR 0.92; 95% CI 0.50, 1.70); other
outcomes included change in EQ-5D index scores (MD
0.09; 95% CI 0.19, 0.02), change in EQ-5D VAS (MD 4.8;
95% CI –12.5, 2.8) and number of items prescribed (MD
−0.87; 95%CI –1.66, −0.08).
• Pope et al was an RCT comparing specialist geriatric input
and medication review compared with usual care (review as
required by a medical officer) in 225 people in
continuing-care wards over 6 months' follow-up.21 The
primary outcomes were number of drugs prescribed
(statistical measures of effect not reported) and medication
cost (net reduction in total medication cost = £20 per
person)
• Zermasky et al was an RCT comparing clinical medication
review by a pharmacist with usual care in 661 older people
living in care homes over 6 months.22 The outcomes
included number of repeat drugs per patient at follow-up
(MD 0.98; 95% CI 0.92, 1.04), hospitalisations per patient
(OR 0.75; 95% CI 0.52, 1.07), mortality (OR 0.89; 95% CI
0.56, 1.41), drug cost (MD –£0.70; 95% CI –£7.28, £5.71)
and number of GP consultations (MD 1.03; 95% CI 0.93,
1.15)
• Sturgess et al was an RCT comparing a structured
pharmaceutical care programme with usual care in 191
community-dwelling older people over 18 months'
follow-up.23 The outcomes included health-related quality
of life measured with SF-36, number of hospitalisations,
prescribed drug use, compliance to medication, number of
contacts with healthcare professionals and cost of
healthcare per patient. Only the P value of the effect was
reported, not the summary measure of effect
• No effect on all-cause mortality and low levels of statistical
heterogeneity (random effects; OR 1.02; 95% CI 0.84 to
1.23; N = 25 studies; I-squared = 8%; OR 1.05; 95% CI 0.85,
1.29; N = 16 RCTs; I-squared = 12%)
• Very low quality evidence on the effect of interventions on
hospitalisation
• Limited evidence on reduction of polypharmacy
(Continues)
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TABLE 1 (Continued)
Study
Definition of polypharmacy
for included studies
Total number of
studies (UK) Included UK studies Key findings across all included studies
Kua et al24 Not defined 41 (8) • Ballard et al examined the discontinuation of neuroleptics by
doctors and pharmacists over 3 months in 100 people and
over 12 months in 165 people25,26
• Ballard et al examined medication review using dementia
guidelines by doctors over 9 months in 277 people27
• Fossey et al examined education training and support on
alternatives to drugs for the management of agitated
behaviour in dementia by pharmacists over 12 months in
359 people28
Furniss et al examined medication reviews by doctors and
pharmacists over 3 months in 330 people29
Jordan et al examined adverse drug reaction profiling by
nurses over 6 months in 43 people30
• Patterson et al examined medication review using a review
model by pharmacists over 12 months in 334 people31
• Zermanky et al examined medication review by pharmacists
over 6 months in 661 people22
• Deprescribing was associated with lower mortality risk,
although the studies' results were highly heterogeneous
• No evidence to suggest an effect of deprescribing on falls
and hospitalisation risk
• Evidence to suggest that deprescribing reduced PIMs
Page et al32 Not defined 115 (15) • Five studies were RCTs: Hearing et al on the deprescription
of atenolol,33 Ballard et al on the deprescription of
antipsychotics,25,26,34 Curran et al on the deprescription of
benzodiazepines,35 Borrill et al on the deprescription of
inhaled fluticasone and salmeterol,36 Choudhury et al on the
deprescription of inhaled corticosteroids37
• Three nonrandomised comparative studies: Minett et al on
the deprescription of donezepil,38 Cunnington et al on the
deprescription of dopamine agonists,39 Jarad et al on the
deprescription of inhaled corticosteroids40
• Seven studies were before-and-after studies: Alsop et al and
Fortherby et al were before-and-after studies on the
deprescription of antihypertensives,41,42 Jackson et al on
the deprescription of nitrates,43 Sambu et al on the
deprescription of clopidogrel,44 Esselinckx et al on the
deprescription of prednisolone,45 Fair et al46 and Daly and
Edwards on the deprescription of digoxin47
• No effect on mortality (OR 0.82, 95% CI 0.61, 1.11; N = 10
studies, n = 3151 people; I-squared = 23%).
• Some evidence to suggest that deprescribing polypharmacy
leads to a reduction in the number of medicines and to a
reduction in the number of PIMs
• No evidence was found to suggest an increased risk of
adverse outcomes and some evidence was found on
benefits
Rankin et al48 ≥4 medications 32 (0) None in UK • Evidence synthesis focussed on pharmaceutical
care + standard care vs standard care
• Statistically significant effect on medication appropriateness
(random effects; MD −4.76; 95% CI –9.20, −0.33; N = 5
studies, n = 517; I-squared = 95%); number of PIMS
(random effects; SMD −0.22; 95% CI –0.38, −0.05; N = 7
studies; n = 1832; I-squared = 67%), proportion of patients
with one or more PPOs random effects; RR 0.40, 95% CI
0.18, 0.85; N = 5 studies; n = 1310; I-squared = 90%)
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TABLE 1 (Continued)
Study
Definition of polypharmacy
for included studies
Total number of
studies (UK) Included UK studies Key findings across all included studies
• Non-significant effect on the proportion of patients with
one or more PIMs (random effects; RR 0.79; 95% CI 0.61,
1.02; N = 11 studies, n = 3079; I-squared = 85%); no
consistent effect on medication-related problems; no
evidence of impact on quality of life or hospitalisations
Topic: Efficient handover between primary and secondary care (2 UK studies out of 25)
Redmond et al49 ≥5 medications 25 (2) • Cadman et al was an RCT comparing a standardised
operating procedure based on hospital guidelines to deliver
medication reviews by trained MRP within 24 hours of
admission and at point of transfer of care out of hospital
against usual care in 200 people at hospital admission.50
The outcomes included length of stay (MD −0.40; 95% CI –
2.08, 1.29), unintentional discrepancies (not reported),
hospital readmissions (RR 0.86; 95% CI 0.58, 1.28),
mortality (RR 0.75; 95% CI 0.27, 2.08) and EQ-5D-3 L index
scores (not reported)
• Bolas et al was an RCT comparing a medicines reconciliation
intervention with standard clinical care in 243 people after
an emergency or unplanned admission to a hospital in
Northern Ireland.51 The primary outcome was unclear; other
outcomes included Eadon scores, medicines discrepancies,
emergency readmission rates and rates of reconciliation. No
results were reported
• Medicine reconciliation interventions reduced the
proportion of people with at least one medication
discrepancy compared to standard care (random effects; RR
0.53; 95% CI 0.42, 0.67; N = 20 RCTs, n = 4,629;
I-squared = 91%)
Non-significant reductions in the number of discrepancies per
person and the number of discrepancies per participant
medication, with high levels of statistical heterogeneity
• Limited effect on PADEs (RR 0.37. 95% CI 0.09, 1.57; N = 3
RCTs; n = 1253; I-squared = 84%) or on ADEs (RR 1.09,
95% CI 0.91 to 1.30; N = 4 RCTs; I-squared = 0%).
• Conflicting evidence on healthcare utilisation: RR on
composite measure of emergency department,
rehospitalisation 0.78; 95% CI 0.50, 1.22; N = 4 RCTs;
n = 1363; I-squared = 48%)
Abbreviations: ADEs, adverse drug events; CI, confidence interval; EQ-5D, standardised instrument for measuring generic health status (not an acronym); MD, mean difference; MRP, medication reconciliation
pharmacist; OR, odds ratio; PADEs, preventable adverse drug events; PIM, potentially inappropriate medicine; PIP, potentially inappropriate prescribing; PP, problematic polypharmacy; PPO, potentially prescrib-
ing omission; RCT, randomised controlled trial; RR, relative risk; SF-36, 36-Item Short-From survey; SMD, standardised mean difference; STOPP, Screening Tool of Older People's potentially inappropriate
Prescriptions.
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Both Jokanovic et al24 and Leelakanok et al32 suggested that
there is no consensus in the literature on the definition of
polypharmacy. Jokanovic et al18 found that the prevalence of
polypharmacy in people residing in long-term care facilities was high.
Leelakanok et al32 found that polypharmacy is associated with greater
risk of death, although this may not reflect a causal effect due to
confounding in the meta-analysis. Hill-Taylor et al18 found that the
prevalence of PIPs varied and that higher prevalence was associated
with older age, female sex, polypharmacy and comorbidities. The
review found some evidence on direct costs of PIP outside of the
UK (Table 1),17,20,21 but not cost-effectiveness.
3.4 | Burden of problematic polypharmacy: Quality
assessment
Table 2 presents the results from the AMSTAR-2 quality assessment.
The AMSTAR-2 quality assessment indicated some limitations relating
to lack of clarity on an a priori protocol,24,32 sources of funding of the
included studies24,32 and details on the excluded studies.24,32 There
were also AMSTAR-2 quality limitations in the meta-analysis by
Leelakanok et al,32 in that estimates from different study designs,
analytical approaches and quantities were pooled together. Hence,
the results of their review should be interpreted as evidence of
association, albeit uncertain, and not as evidence of a causal effect.
Furthermore, the authors did not clearly define the inclusion criteria
for studies, report on the study selection process or consider study
quality in the meta-analysis.
3.5 | Interventions to reduce problematic
polypharmacy: Findings
Six systematic reviews were on the topic of interventions to reduce
problematic polypharmacy,9,13,16,18,19,48,49 one of which was on the
effectiveness of deprescribing guidelines to reduce problematic
F IGURE 1 PRISMA 2009 flow diagram
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polypharmacy.13 No systematic reviews were found that evaluated
the effectiveness of using routine data to reduce problematic
polypharmacy or the effectiveness of digital technologies to reduce
problematic polypharmacy.
Clyne et al16 evaluated the effectiveness of interventions to
reduce PIP in community-dwelling older adults. The review
included 12 studies, none of which were undertaken in the
UK. Page et al48 evaluated the safety, effectiveness and feasibility
of deprescribing interventions on mortality and other health
outcomes. The review included 115 studies, 15 of which were UK
studies on deprescribing.22,23,25–31,33–40 Hill-Taylor et al19 evaluated
the effectiveness of the STOPP/START criteria (likely to be version
141 from the dates of the included studies). The review included
four studies (one of which was in also in Hill Taylor18), none of
which were undertaken in the UK. Kua et al13 evaluated the
effectiveness of deprescribing on polypharmacy in people living
in nursing homes. The review included 41 studies, eight of
which were UK studies evaluating discontinuation,25,26 medication
review,42–45 education training and support on alternatives,46 and
adverse drug reaction profiling.47 Rankin et al49 evaluated the
effectiveness of interventions to improve the appropriate use of
polypharmacy and reduce medication-related problems in older
people. The review included 32 studies, none of which were
undertaken in the UK.
All of these systematic reviews found that the interventions
they evaluated were effective at reducing problematic
polypharmacy.13,16,19,48,49
Hill-Taylor et al18,19 also concluded that the STOPP/START
criteria could be useful to help identify people at risk of potentially
inappropriate prescribing, but concluded that more research is
required on its feasibility and effectiveness.
Johansson et al9 undertook a systematic review and meta-
analysis of the effectiveness of interventions to reduce polypharmacy
on mortality, hospitalisation and number of drugs in elderly patients
and included 25 studies. The review included four UK studies on
medication review45,50,51 and pharmaceutical care programmes.52 The
review found no effect on all-cause mortality, as did Page et al48 and,
to some extent, Kua et al.13 Both Johansson et al9 and Clyne et al16
also found that there was no clear evidence of an effect on clinically
relevant patient outcomes.
From a safety perspective, Page et al48 found no evidence to
suggest that deprescribing increases the risk of adverse outcomes.
From the reviews by Page et al,48 Kua et al13 and Rankin et al,49 the
evidence was mixed on the effect on disease-specific outcomes,
quality of life and hospitalisations.
3.6 | Interventions to reduce problematic
polypharmacy: Quality assessment
The AMSTAR-2 quality assessment indicated some limitations relating
to lack of clarity on an a priori protocol,13 sources of funding of the
included studies13,16,49 and details on the excluded studies.13,16,18,19T
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There were also AMSTAR-2 quality limitations in the meta-analysis
by Kua et al13 given the choice of fixed-effects (rather the random-
effects) in the presence of statistical heterogeneity. None of the
five reviews presenting a meta-analysis considered study quality in
the analysis.13,18,19,48,49
3.7 | Implementation activities to improve uptake of
interventions to reduce problematic polypharmacy
No systematic reviews were found on this topic.
3.8 | Efficient handover between primary and
secondary care to reduce problematic polypharmacy:
Findings
One of the included systematic reviews was on the topic of efficient
handover between primary and secondary care to reduce problematic
polypharmacy.10
Redmond et al evaluated the effectiveness of medicines
reconciliation on medication discrepancies, patient-related outcomes
and healthcare utilisation during care transitions. The review included
25 studies, two of which were undertaken in the UK. One UK study
evaluated a standardised operating procedure based on hospital
guidelines to deliver medication53 and the other evaluated a
medicines reconciliation intervention.54 The review found that the
interventions implemented in the included studies reduced medication
discrepancies at care transitions, although the evidence was deemed
to have very low certainty. There was little or no effect on
adverse drug events, preventable adverse drug events or health care
utilisation, although these findings are also uncertain due to the
methodological quality of the primary studies observed by the
review authors. The review authors also identified the possibility of a
publication bias in the review.
3.9 | Efficient handover between primary and
secondary care to reduce problematic polypharmacy:
Quality assessment
The AMSTAR-2 quality assessment (Table 2) indicated some
limitations relating to sources of funding of the included studies and
consideration of study quality in the meta-analysis.
4 | DISCUSSION
4.1 | Summary of findings
This rapid review summarised the evidence on problematic
polypharmacy related to burden, interventions and handover between
primary and secondary care. The rapid review included nineT
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systematic reviews: three on the burden of problematic
polypharmacy,18,24,32 six on interventions to reduce problematic
polypharmacy,9,13,16,18,19,48,49 and one on efficient handover between
primary and secondary care to reduce problematic polypharmacy.10
All reviews were international, with most including some UK studies.
No systematic reviews were found on implementation activities to
increase uptake of interventions to reduce problematic polypharmacy.
For the topic of the burden of problematic polypharmacy, the
evidence from one review suggests that the prevalence of
polypharmacy in people residing in long-term care facilities is high,
although it varies widely by country, setting and definition of how
many medicines constitute polypharmacy.24 The UK studies in the
review found that the majority of people in long-term care facilities
were on multiple medicines.11,12,14 The evidence on the association
between polypharmacy and greater mortality risk was mostly
international. However, due to confounding bias in the evidence, any
association is unlikely to reflect a causal effect. From one systematic
review,18 three studies were found on the costs due to problematic
polypharmacy, but none was in the UK.17,20,21 For these reasons, the
prevalence of polypharmacy and problematic polypharmacy, and
the costs and health consequences due to problematic polypharmacy
in the UK remain unclear.
For the topic of interventions to reduce problematic polypharmacy,
the evidence suggests that the interventions can reduce problematic
polypharmacy, although reductions in the number of medicines are
more uncertain. Deprescribing and other interventions to reduce
problematic polypharmacy appear to have no effect on all-cause
mortality, but there is no clear evidence of an effect on other clinically
relevant outcomes, quality of life and hospitalisations.
For the topic of efficient handover between primary and secondary
care to reduce problematic polypharmacy, there is some evidence
that medicine reconciliation activities reduce medication discrepancies
at care transitions, although the quality of the evidence is low.
4.2 | Summary of methodological quality
Across all topics and reviews, the AMSTAR-2 quality assessment was
variable, with limitations observed relating to lack of clarity on an a
priori protocol, sources of funding of the included studies, details
of excluded studies and consideration of study quality in the
meta-analysis (where undertaken).
For one systematic review on the topic of the burden of
problematic polypharmacy32 and one on the topic of interventions to
reduce problematic polypharmacy,13 there were also some
concerns with the AMSTAR-2 domain regarding the methods for the
meta-analysis, indicating that the results from these reviews should
be interpreted with caution.
4.3 | Areas for future research
For the topic of the burden of problematic polypharmacy, as the
existing systematic reviews suggest that there is no consensus in the
literature on the definition of polypharmacy, the prevalence of
polypharmacy in people residing in long-term care facilities is high and
there may be an association between polypharmacy and mortality risk
in various populations and settings, further research is warranted:
• To estimate the prevalence of polypharmacy and the prevalence of
problematic polypharmacy in all UK settings, according to a
definition that represents the current expert consensus.
• To identify the factors that predict problematic polypharmacy in
the UK with the aim of routinely identifying people at risk of
problematic polypharmacy and who should be prioritised for
interventions to reduce problematic polypharmacy.
• To estimate the causal effect of problematic polypharmacy on
costs and on health outcomes; in other words, what would have
been the costs and health outcomes of a group of people exposed
to problematic polypharmacy had they not been exposed to
problematic polypharmacy?
This could be undertaken by further systematic review work,
including an update of the existing reviews to identify further UK
studies, along with further primary investigation studies undertaken in
the UK. Further work could also involve using routinely collected
electronic health records to estimate prevalence of problematic
polypharmacy, identify predictive factors and infer causal effects.
For the topic of interventions to reduce problematic
polypharmacy, given that the existing systematic reviews have found
that, although the interventions were effective at reducing
problematic polypharmacy there is no clear evidence of an effect on
clinically relevant patient outcomes, the areas for future research are:
• The comparative effectiveness of each intervention to reduce
problematic polypharmacy, considering the quality of the primary
studies and their generalisability to the UK and considering the role
of routine data and digital technologies. Answering this research
question could involve an update of the existing reviews.
• To estimate the resources and costs required to implement and
run the various interventions.
• To estimate the cost-effectiveness of the interventions, with
cost-effectiveness modelling of the long-term costs and health
outcomes of current practice with or without interventions, given
the prevalence of problematic polypharmacy, the consequences
of problematic polypharmacy on costs and health outcomes,
and the effectiveness of interventions in reducing problematic
polypharmacy.
Given the lack of systematic review evidence on implementation
activities to increase uptake of interventions to reduce problematic
polypharmacy, future research (both systematic review and primary
research) could explore the following areas:
• To understand the extent to which interventions to reduce
problematic polypharmacy are used in the UK and, if uptake is
suboptimal, to identify the barriers to uptake and the implementation
activities that could address these.
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• To review the literature and conduct evidence synthesis to estimate
the comparative effectiveness of the relevant implementation
activities in changing uptake, considering the quality of the primary
studies, their design (eg, pragmatic trials) and their generalisability to
the UK. Future reviews should prespecify the implementation
activities on which evidence is sought on (eg, electronic decision
support tools, tools for shared decision-making, etc)
• To conduct cost-effectiveness modelling of the value of
implementation given the current uptake, the effectiveness of
implementation activities, the cost-effectiveness of interventions
to reduce problematic polypharmacy and the prevalence of
problematic polypharmacy.
For the topic of efficient handover between primary and
secondary care to reduce problematic polypharmacy, an update of the
single systematic review of medicines reconciliation could be
undertaken to identify further UK studies on this topic and to inform
further primary research to consider, in addition to effectiveness,
effect on adverse drug events, preventable adverse drug events,
cost and healthcare utilisation, alongside consideration of the
generalisability of the studies and feasibility of interventions to the
UK setting. Further systematic reviews of other interventions for
efficient handover between primary and secondary care to reduce
problematic polypharmacy could also be undertaken.
4.4 | Strengths and limitations
Given the time and resource constraints, this rapid review does have
some limitations. Due to single reviewer study selection, it is possible
that eligible systematic reviews may have been missed at the study
selection stage. The systematic review searches were highly specific,
which may have also led to some relevant systematic reviews being
missed. We adopted an abbreviated rapid review method in selecting
and searching fewer, but relevant databases. The impact of searching
beyond three databases was not investigated. Also, the search date
restriction may have missed some key primary publications on
medication reconciliation and problematic polypharmacy, although
many of the reviews included studies published since the year 2000
and before.
Our rapid review methods, in which we abbreviated certain
methodological aspects of the systematic review process, offered a
pragmatic alternative to a systematic review, given the wide range of
commissioned topics and questions, and the two-month timeframe to
present the findings to the DHSC. Time permitting, a systematic
review applying Heath Technology Assessment methods would have
been considered. However, the rapid review approach allowed us to
summarise the literature on the topics of interest and identify the
areas where more research is required.
The systematic reviews included in this rapid review were not
solely UK focused. As such, we included systematic reviews using any
definition of polypharmacy, where the King's Fund definition was not
used for selecting included studies. Definitions of polypharmacy used
by reviews were often not reported or varied in the number of
medications. Due to the time constraints of this commissioned
rapid review, we were unable to extract the polypharmacy definitions
of the included UK studies.
The systematic reviews included in the rapid review were
published between 2013 and 2019, with searches undertaken some
months prior to publication. As such, more recent evidence on the
topics for this rapid review will not have been captured, and we were
unable to supplement our rapid review with updated searches to iden-
tify newer evidence.
5 | CONCLUSIONS
This rapid review has summarised the evidence from existing
systematic reviews on the burden of polypharmacy, interventions to
reduce it and efficient handover between primary and secondary care
to reduce it. No systematic reviews were found that evaluated the
effectiveness of using routine data to reduce problematic
polypharmacy, the effectiveness of digital technologies to reduce
problematic polypharmacy or implementation activities to improve
uptake of interventions. Most reviews included some UK studies.
The conclusions from this rapid review are that across existing
systematic reviews there is no consensus in the primary evidence
base on the definition of polypharmacy, the prevalence of
polypharmacy in people residing in long-term care facilities is high and
associated with greater mortality risk (although the link is unlikely to
be causal), interventions to reduce problematic polypharmacy are
effective but there is no evidence on clinically relevant patient
outcomes, and there is some evidence that medicine reconciliation
activities reduce medication discrepancies at care transitions, although
the evidence has very low certainty.
In the UK, the prevalence of polypharmacy has increased
over time. Problematic polypharmacy is a key area of interest for
UK health policy. The systematic reviews included here provide
very little reliable information on the extent of problematic
polypharmacy in the UK, what interventions to address it are
effective and the cost-effectiveness of interventions in the UK
setting. There are also methodological issues with the existing
systematic reviews, alongside the age of the existing systematic
review searches. Therefore, a number of research questions are
proposed to address the evidence gaps and to help directly inform
UK policy on the topic.
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APPENDIX 1
Pragmatic Medline search strategy
# Searches
1 Polypharmacy/
2 Polypharma*.Ti,ab.
3 Polytherap*.Ti,ab.
4 ((multi-drug* or multidrug*) adj2 (prescrib* or prescription* or therap* or treatment*)).Ti,ab.
5 Inappropriate prescribing/
6 Potentially inappropriate medication list/
7 ((inappropriat* or unnecessary or multipl*) adj2 (medicine* or medicat* or prescrib* or prescription* or drug*)).Ti,ab.
8 ((over adj1 (prescrib* or prescript*)) or (over-prescrib* or overprescrib*)).Ti,ab.
9 Deprescriptions/
10 (deprescrib* or deprescript*).Ti,ab.
11 Or/1-10
12 MEDLINE.Tw.
13 Systematic review.tw.
14 Meta analysis.pt.
15 12 or 13 or 14
16 11 and 15
17 Limit 16 to elderly
18 Limit 17 to (English language and yr = “2009 -current”)
MARTYN-ST JAMES ET AL. 15
APPENDIX 2: EXTRACTED DATA FROM THE INCLUDED SYSTEMATIC REVIEWS
Data extraction of the methods of the included systematic reviews
Study Objectives Patient population Interventions comparators Outcomes
Jokanovic et al [12] To investigate the prevalence
and the factors associated
with polypharmacy
in long-term care facilities
People resident in long-term
care facilities
Exposure to polypharmacy
Polypharmacy clearly defined
Prevalence of polypharmacy
Leelakanok et al [14] To summarise the literature
and conduct a meta-analysis
of the association between
polypharmacy and
mortality risk
Adults (studies in children
were excluded)
Exposure: Polypharmacy as
multiple medication use,
with explicit number of
medications that were
considered as polypharmacy
Outcomes: Death, reported in
a way that can be used to
calculate risk ratios (OR,
RR, HR)
Clyne et al [8] To review and determine the
effectiveness of
interventions to reduce
PIP in community-dwelling
older adults
Included: Community-dwelling
older adults (aged ≥65 or had
an average age of ≥65)
Excluded studies in which more
than 20% of the subject
population was described as
institutionalised (eg, nursing
homes, residential care homes
or geriatric inpatients)
Studies that focused on the
reduction of inappropriate
prescribing in one drug
class only were also excluded
Intervention: An intervention
intended to improve PIP in
primary care, including but
not restricted to
organisational, professional,
financial, regulatory or
multifaceted interventions
Comparator: Usual care or
alternate intervention
Primary outcome: Change in
PIP, measured using
specified implicit or explicit
tools (eg, beers, STOPP,
MAI)
Hill-Taylor et al [9, 10] To update the 2013 systematic
review using new evidence
from RCTs that assess the
effectiveness
of STOPP/START criteria on
prescribing quality and clinical,
humanistic and economic
outcomes in adults aged
65 years and older
Adults aged 65 years and older Intervention: STOPP/START
criteria
Comparator: Not reported
2013: Indicators of the clinical
and humanistic impact of
the use of STOPP/START
criteria on the patient and
healthcare system (ADEs,
physician visits, emergency
department visits,
hospitalization and quality
of life)
2016: Studies that measured
robust indicators of the
clinical, humanistic
and economic impact of the
application of the criteria
Outcome for the meta-
analysis was odds ratio of
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Study Objectives Patient population Interventions comparators Outcomes
patients having at least
one PIM after intervention
Johansson et al [11] To review strategies to assess and
reduce inappropriate polypharmacy
in elderly patients on relevant
clinical outcome measures such as
mortality and hospitalisation
Included: Older patients age
≥ 65 years (or 80% of study
population aged ≥65 years) with
polypharmacy, 4 or more
prescribed or nonprescribed
drugs (or 80% of study
population taking ≥4 drugs)
Excluded: Approaches
investigating under prescription
(eg, “start interventions”)
and interventions focusing on
people receiving short-term
polypharmacy (eg, terminally ill
or receiving cancer
chemotherapy)
Interventions: Electronic
strategies to reduce
polypharmacy (clinical
decision support,
computerized physician
order entry, others)
Comparators: No intervention
or usual care (other
comparable intervention)
Primary: Mortality,
hospitalisation, change in n
drugs
Secondary: Morbidity, QoL,
mental and physical function,
ADEs, medication error/
inappropriate, focus of care,
user/patient satisfaction,
adherence, resource
utilisation, and costs
Kua et al [13] To review the effects of
deprescribing
studies on clinical
outcomes that
have been performed
among older
residents in
nursing homes
Included: Nursing home residents
≥60 years of age
Excluded: Terminal or palliative
care-requiring nursing home
residents
Intervention: Drug
discontinuation defined as
either medication
discontinuation, substitution
or reduction
Any reported health outcomes
(including falls, inappropriate
medications, all-cause
mortality,
and hospitalisation rates)
Page et al [15] To review the safety,
effectiveness
and feasibility of
deprescribing
interventions on
mortality and
health outcomes
Included: Patients aged 65+ years
on 1+ regular medicines
Excluded: Patients at the end of
life
Setting: Any
Interventions: Deprescribing
by a healthcare professional
of medicines available in
2015 (excludes medicines
withdrawn from the market)
Comparators: Usual care
(ie, continuation of
medication)
Studies were pooled as
“polypharmacy” where the
stated aim or effect of the
intervention was to reduce
medications across three or
more medications or
classes
Primary outcome: Mortality
Secondary outcomes:
Reported adverse drug
withdrawal events,
clinically relevant physical
health, cognitive function,
psychological health, quality
of life using any
standardised tool
Rankin et al [16] To review the effectiveness of
interventions to improve the
appropriate use of
polypharmacy
and reducing medication-
Included: People aged 65 years
and older, who had more than
one long-term medical
condition and were receiving
All types of interventions
aimed at improving
appropriate polypharmacy
in any setting (such as
pharmaceutical care)
Validated measures of
inappropriate prescribing
such as beers criteria,
MAI, STOPP/START criteria,
or assessing Care of
(Continues)
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Study Objectives Patient population Interventions comparators Outcomes
related problems
in older people
polypharmacy (classified as four
or more medicines
Excluded: Studies in which the
intervention focused on people
with a single long-term medical
condition or who were
receiving short-term
polypharmacy
compared with usual care
(as defined by the study)
Vulnerable Elderly
(ACOVE) that assessed
primary outcomes
(medication
appropriateness, potentially
inappropriate medications,
potential prescribing
omissions, hospital
admissions) and secondary
outcomes (medication-
related problems, eg, AEs,
adherence,
quality of life)
Redmond et al [17] To review the effectiveness of
interventions fulfilling
the Institute
for Healthcare Improvement
definition of medication
reconciliation aimed at
all patients
experiencing a
transition of care
Included: Patients experiencing a
transition of care
Care transitions referred to
changes in the level, location or
providers of care as patients
moved within the healthcare
system
Excluded: Trials investigating
interventions to improve the
quality of prescribing during
care transitions, with no
medication reconciliation focus
Studies where the
intervention
was broadly
compliant with
the process of medication
reconciliation as outlined
by the Institute for
Healthcare Improvement
The intervention must have
been applied as patients
transitioned from different
levels or locations of care
(or both)
Primary: Medication
discrepancies
Secondary:
Participant-related
and process outcomes,
healthcare utilisation,
additional outcomes
(including AEs)
1
AE, ; ADE, ; ARR, absolute risk reductions; B&A, ; CI, ; HC, ; JBI, ; MAI, ; PIM, ; QA, ; QoL, ; QUIPS, ; RCT, ;RoB, RR, STOPP/START,Data extraction of the results of the included systematic reviews (number of
studies, study design, population, setting, interventions/exposure and risk of bias)Data extraction on the results of the systematic reviews (outcomes)Data extraction on the conclusions of the included systematic
reviews
Study Types of studies Study selection Data extraction Quality assessment Data synthesis and analysis
Jokanovic et al [12] Not defined One investigator s
creened the
abstracts
Two investigators
assessed full
text independently, and
disagreements resolved
by third investigator
Two investigators extracted
the data independently
using a standardised data
extraction tool
Tool adapted from JBI
critical appraisal
checklist for
descriptive/case series
Two investigators did the
QA independently, and
disagreements resolved
by a third investigator
Narrative synthesis
Leelakanok et al [14] Not review articles; not case
reports or case series
One researcher screened
titles and abstracts
Abstracts reviewed by two
authors independently
Standardised data
extraction form
Two researchers
did the data
extraction
independently
Two researchers did the
QA independently and
disagreements resolved
by consulting two other
researchers and by
consensus
Random effects models
with inverse variance
weighting; I-squared
< 30% was considered
as negligible
heterogeneity
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Study Types of studies Study selection Data extraction Quality assessment Data synthesis and analysis
In case of disagreements,
two other researchers
were consulted and
disagreements were
resolved by consensus
Used the
Newcastle-Ottawa
quality assessment
scale (scores 1-9)
Studies scoring 1-3 were
considered low quality,
4-6 medium quality,
7-9 high quality
Stratification by type of
risk ratio, number of
medications, HC setting
(community, hospital,
institutional)
and study quality
Number of polypharmacy
classifications
categorised
in three groups:
studies
defining
polypharmacy as
a discrete variable, studies
dichotomising
polypharmacy
using thresholds of <10
drugs (polypharmacy),
studies
dichotomising
polypharmacy
using thresholds of
10+ drugs
(excessive polypharmacy)
Funnel plot for
publication bias
Clyne et al [8] Randomised controlled trials
and cluster randomised
controlled trials only
Three reviewers independently
assessed studies for eligibility
Three reviewers
independently
extracted data
Methodological quality
was assessed using the
Cochrane
Collaboration's
risk of bias tool
The studies identified were
too heterogeneous in terms of
their outcome measures and
intervention types to
conduct a meta-analysis,
so a narrative summary
was performed
Where appropriate, crude
odds ratios and ARRs
were calculated
Hill-Taylor et al [9, 10] 2013: Randomised trials and
non-randomised study
designs investigating the
impact and application of
the STOPP/START
2016: RCTs involving the
prospective application of
the STOPP and/or START
criteria
2013: Study selection was
performed independently
in an unblinded standardised
manner by two authors
(DOS and BHT)
2016: Two review authors
independently appraised
the search results for
eligibility (KW and BHT).
2013: Two authors
independently
performed the data
extraction
(DOS and BHT)
One author checked
extracted
data for agreement (BHT)
2016: Both review authors
independently abstracted
2013: Methodological
quality was
assessed using
the Cochrane
Collaboration's
risk of bias tool and
modified quality
assessment scale initially
designed for studies of
2013: Heterogeneity of
study populations,
interventions and study
design precluded
meta-analysis
Descriptive analysis was
performed
2016: A random-effects
meta-analysis to
synthesise evidence on
(Continues)
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Study Types of studies Study selection Data extraction Quality assessment Data synthesis and analysis
data from selected
studies (KW and BHT).
prognostic factors
(QUIPS)
2016: Cochrane RoB
the effectiveness of the
STOPP criteria on
reducing the PIM rate
in patients due to
anticipated clinical
heterogeneity
A narrative synthesis
was performed for
all other outcomes
Johansson et al [11] All types of controlled studies
(randomised controlled
trials, cluster randomised
controlled trials,
nonrandomised controlled
trials, cohort studies and
case control studies)
Two reviewers independently
screened each title and
abstract for eligibility
One author extracted the
data and a second author
independently extracted
the data and then checked
the completeness
Risk of bias was assessed
according to the Cochrane
collaboration handbook
The quality of the evidence
was assessed using the
grading of
recommendations,
assessment, development
and evaluation (GRADE)
methodology
Four of 25 included studies
where not RCTs, but
were quality
assessed using RoB
Random effects
meta-analysis and
sensitivity/subgroups
on methodological
quality and length
of follow-up
Kua et al [13] Randomised controlled trials Not reported Two investigators
extracted
the data and
reviewed each
entry for accuracies
Two investigators
undertook quality
assessment
Fixed and random effects
(where Cochran Q
test P value <0.05)
meta-analysis and
subgroups by
intervention type,
medication type,
intervention provider
and study location
Page et al [15] Any comparative design:
RCTs, quasi-randomised
controlled studies,
nonrandomised controlled
studies, cohort studies,
case-control, 2+ single-
arm studies, B&A studies;
in English
Two researchers independently
for all titles, abstracts and
full-text studies
Disagreements resolved
by consensus
Standardised data
extraction form
Extraction by one researcher
and verified by a
second researcher
Authors of original studies
contacted for missing or
unclear information
Assessment of risk of bias
done with Cochrane risk
of bias tool for RCTs
and a modified tool for
non-RCTs, done by two
researchers independently
Studies meta-analysed
where possible
Studies pooled as
“polypharmacy”
where 3+ medication
classes were targeted
for deprescribing
Heterogeneity assessed
with I-squared
(I-squared ≤50%)
or P > 0.1
Subgroup analyses when
more than 10 studies
were found for the same
target medication; based
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Study Types of studies Study selection Data extraction Quality assessment Data synthesis and analysis
on age (under or above
80 years of age),
cognitive function (with
or without dementia),
and intervention method
(patient-specific
interventions or
educational programmes)
Patient-specific interventions
are those when the
investigators identified
target medications to
deprescribe and
implemented the
process/asked prescribed
to implement it
Rankin et al [16] Randomised controlled trials,
cluster-randomised trials,
nonrandomised trials,
controlled before-after
studies and interrupted
time series
Three reviewers (AR, CAC
and JC) independently
screened titles
and abstracts
Three reviewers (AR, CAC
and JC) independently
extracted data
Risk of bias was assessed
according to the
Cochrane
collaboration handbook
The quality of the evidence
was assessed using the
grading of
recommendations,
assessment,
development and
evaluation (GRADE)
methodology
In the presence of
statistical heterogeneity
(greater
than 50%, as estimated
by the
I2 statistic), applied a
random-effects model
for meta-analysis
For pooling, only groups of
studies of the same design
(randomised trials and
nonrandomised
trials)
When it was not possible
to combine outcome
data because
of differences in
reporting or
substantive
heterogeneity, a
narrative summary
was reported
Redmond et al [17] Randomised controlled
trials
Two review authors
independently
screened titles
and abstracts
Two review authors
independently
undertook data
extraction
Modified Cochrane RoB
The quality of the
evidence was assessed
using the grading of
recommendations,
assessment,
development and
Pooled estimates
(RRs with 95% CIs) of
the evaluated outcome
measures were
calculated by the
generic inverse
variance method
(Continues)
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Study Types of studies Study selection Data extraction Quality assessment Data synthesis and analysis
evaluation
(GRADE) methodology
Where it was not
possible to synthesise
the data from the
included studies, a
narrative synthesis of
the results, grouping
together studies that
used similar interventions
and provided a comparison
of different approaches,
was undertaken
aAE, ; ADE, ; ARR, absolute risk reductions; B&A, ; CI, ; HC, ; JBI, ; MAI, ; PIM, ; QA, ; QoL, ; QUIPS, ; RCT, ;RoB, RR, STOPP/START,
bData extraction of the results of the included systematic reviews (number of studies, study design, population, setting, interventions/exposure and risk of bias)
cData extraction on the results of the systematic reviews (outcomes)
dData extraction on the conclusions of the included systematic reviews
Data extraction of the results of the included systematic reviews (number of studies, study design, population, setting, interventions/exposure and risk of bias)
Study Number of studies Study design Population Setting Interventions/exposure Risk of bias
Jokanovic
et al [12]
N = 153 records after
duplicates removed;
44 studies included in the
review (total number of
study participants not
reported)
Not summarised Residents in LTCFs with
mean age ranged
61.7-86.0 years
Four studies focused on
residents with lengths of
stay longer than 1 or
3 months, four studies
focused on residents with
cognitive impairment, two
studies on residents
presented to hospital, in
residents with diabetes,
one in residents who had
experienced a fall, one in
veteran
LTCFs Exposure was polypharmacy
Medication use was
ascertained from
medication charts or
medical records (n = 24),
drug registers or
databases (n = 6),
administrative or
minimum data sets (n = 5),
resident interviews (n = 1)
and
pharmacist-conducted
medication reviews
(n = 1)
Polypharmacy defined as 5+
medicines (n = 11), 9+
medicines (n = 13), 10+
medicines (n = 11)
All studies reported clearly
defined inclusion criteria,
42 (95%) studies used
objective criteria to
assess outcomes,
20 (45%) studies aimed to
have participants who
were representative of all
residents in the particular
LTCF, 37 (84%) studies
did not identify and
control for confounding
factors using multivariate
analyses
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Study Number of studies Study design Population Setting Interventions/exposure Risk of bias
Twenty-four studies
included the use of all
medications taken
regularly and as needed
to assess polypharmacy,
six studies included only
regular medication,
14 studies included only
prescribed medication,
10 studies excluded
specific medicines from
the polypharmacy
assessment, 11 studies
reported the period of
time during which
exposure was assessed
Leelakanok
et al [14]
N = 3892 studies after
duplicates removed,
47 studies data extracted
and meta-analysed
Of the 47 studies,
26 prospective cohort,
11 retrospective cohort,
five case control, four
clinical trials, one
cross-sectional study
36/47 studies were in
people with mean age 65
+ years, eight in people
with mean age <65 years,
one study did not provide
the age
Not discussed Definition of polypharmacy
varied: 11 studies
measured polypharmacy
as a discrete number of
medications, 12 as 1-4
medicines, 15 as 5+, 9 as
6-9, 11 as 10+. The
methods to determine the
number of medicines
were not discussed in the
review
According to
Newcastle-Ottawa
quality assessment scale,
no studies were low
quality, 19 were medium
quality and 28 were high
quality
Funnel plot indicates some
publication bias against
negative and/or smaller
studies
Clyne et al
[8]
N = 749 records after
duplicates removed,
12 studies included in the
review
12 RCTs, with 156,529
participants
PIP was measured using
implicit criteria in four
studies and explicit
criteria in eight studies;
the MAI was the only
implicit measure
Of the eight studies using
explicit criteria, one used
the beers criteria 1997
iteration, one the 2003
iteration, one used the
McLeod crtieria and five
used combinations of
existing criteria or
study-specific criteria
Across the 12 RCTs the
mean age of participants
ranged from 65 to 81
Baseline PIP prevalence
ranged between 18% and
100%
In the community Six RCTs were on
organisational
interventions (four on
pharmacist interventions
and two on
multidisciplinary team
approaches), two RCTs
were on professional
interventions (targeting
prescribers directly) and
four RCTs were on
multifaceted
interventions (combining
two or more techniques)
Detection, attrition and
reporting bias were low in
most studies
Randomization, allocation
concealment and blinding
were less reliably
implemented or reported
Protection against
contamination was
unclear in three cluster
RCTs
All cluster RCTs accounted
for clustering
(Continues)
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Study Number of studies Study design Population Setting Interventions/exposure Risk of bias
Hill-Taylor
et al [9,
10]
2013: N = 77 records after
duplicates removed,
13 studies included in the
review
2016: N = 230 records after
duplicates removed, four
studies included in the
review
2013: 13 studies: a single
randomised controlled
trial and 12 observational
studies
This review includes the
application of
STOPP/START to the
health records of
approximately 344 957
adults
2016: Four RCTs with 1935
participants
2013: The mean age of
participants ranged from
74. 9 to 86.9 years
The majority of participants
were female (from 53% to
80%)
The majority of participants
were from the Northern
Ireland and the Republic
of Ireland
Prevalence of PIP between
21.4% and 79% although
affected by heterogeneity
in sample population and
study design
2016: Participants in all four
studies were at least
65 years of age, although
one study restricted
participants to those aged
75 years and older
The majority of participants
were female (from 53% to
73%)
Healthcare systems from
four nations were
represented (Republic of
Ireland, Belgium, Spain
and Israel)
Baseline PIM between
32.4% and 66.8%
2013: The majority of
participants in the
included studies were
community dwelling
2016: Two RCTs following
discharge from the acute
care, two RCTs in LTCFs
2013: Five studies, including
the RCT, applied the full
STOPP and START
criteria to participant's
medication profiles, three
studies applied the
STOPP criteria, and one
study applied the START
criteria
Seven of the observational
studies compared
STOPP/START with other
explicit criteria
2016: Three RCTs used the
criteria to assess
prescribing quality, one1
RCT conducted in Ireland
used the full STOPP and
START criteria as a
screening tool
2013: Study quality varied.
Seven studies adequately
controlled for bias related
to the study participation,
outcome, application of
STOPP/START and
confounding
measurement domains.
Three were considered at
a low risk of bias due to
methods of data and five
at low risk of bias due to
approach for application
of the STOPP/START
tool. One study was
found to have a high risk
of bias with regard to the
application of the
screening tool. Five
studies were considered
at moderate or high risk
of bias in the statistical
analysis and data
presentation domains
2016: Two RCTs were at a
low risk of bias in all key
domains, but concern
existed regarding the risk
of bias in the other two
RCTs
Johansson
et al [11]
N = 19 052 records after
duplicates removed,
25 studies included in the
review (17 RCTs, four
cluster RCTs, four
nonrandomised
controlled)
Seventeen RCTs, four
cluster RCTs, four
nonrandomised controlled
studies; range 79-2454
per study
The mean age of study
participants ranged from
69.7 to 87.7 years and
the percentage of male
participants ranged from
20% to 100%
Thirteen studies in general
practitioner surgeries, two
studies in primary care
centres/general
practitioner outpatient
clinic, one in an internal
medical clinic, one in a
hospital, one in a chronic
care geriatric facility, one
in a residential hospital
with continuous care
wards, five in nursing
Thirteen studies were
pharmacist-led
interventions, four studies
were physician-led the
interventions and eight
studies were
multidisciplinary team-led
interventions
The main limitations
contributing to risk of
bias were related to the
design (eg, inadequate
randomisation,
intent-to-treat analysis,
sample size and power
calculation) or execution
of the studies
All studies were unclear on
blinding of participants
and personnel
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Study Number of studies Study design Population Setting Interventions/exposure Risk of bias
homes and one in an
assisted living facility
Kua et al
[13]
N = 1171 records after
duplicates removed,
41 RCTs included in the
review
Forty-one RCTs enrolling
18 408 residents
Thirty-four studies mean
age between 80 and
90 years, and 69.4%
female
Fifteen studies specifically
included only dementia
residents
Nursing homes Fourteen studies on drug
discontinuation,
11 studies on the impact
of medication review,
using tools such as beers
criteria or START/STOPP,
six studies on educational
programs
Other interventions
included two case
conferences, two
comprehensive geriatric
assessments, two
outreach visits, one ADE
profiling, one alternative
therapy, two health
technologies and
informatics
The main limitations
contributing to risk of
bias were related to
detection bias, as blinding
of the residents and
intervention/health care
providers was not
possible because of the
nature of the intervention
Page et al
[15]
N = 21 165 records after
duplicates removed,
132 full-text papers
reporting 116 studies
(132 references) included
in the review
Fifty-six RCTs, with 17 428
participants,
22 comparative studies
with concurrent control
group, with 14 522
participants,
37 comparative studies
without concurrent
control group, with 2207
participants
Mean follow-up = 15.5
(SD = 17.4 months)
N = 34 143, mean age 73.8
(SD = 5.4) years, 51.8%
male, mean
age > 80 years in
38 studies (4833 people)
N = 33 studies included
people with dementia
(6090 people)
Fourteen studies in hospital,
29 in residential aged
care, 73 community based
One study included
participants in the
community and
residential aged care, and
another was based in the
community and hospital
Deprescribing one
medication, which could
be a single medicine
(N = 34 studies), a
medicine from a single
class (N = 5 studies) or a
medicine of a
therapeutical category
(N = 27 studies),
withdrawing two
medications (N = 11
studies)
Deprescribing
polypharmacy (3+
therapeutical classes)
N = 21 studies, of which
N = 18 were
patient-specific
interventions (N = 11 led
by doctors, N = 2 led by
pharmacists, N = 1 led by
nurses and N = 1 led by
multidisciplinary teams)
18/56 (32%) RCTs were
rated low risk of bias in at
least 4/7 parameters;
68% of RCTs had unclear
or high risk of bias
Results for non-RCTs not
reported
(Continues)
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Study Number of studies Study design Population Setting Interventions/exposure Risk of bias
N = 10 were
investigator-led
interventions (N = 8 on
medication reviews with
recommendations to the
prescriber, N = 3 on
educational programmes
delivered at residential
aged care facilities to
nurses (N = 1) or to the
prescribing doctors
(N = 2)
Rankin et al
[16]
N = 7526 records after
duplicates removed,
32 studies (including
12 from the previous
update) included in the
review (18 RCTs,
10 cluster RCTs, four
nonrandomised
controlled)
Thirty-two studies:
18 RCTs, 10 cluster RCTs,
two non-RCTs, two
controlled before-after
studies, involving 28 672
older people
Mean age of 72.8 years, all
study participants had
more than one long-term
medical condition
On average, participants
were receiving more than
four medicines at baseline
(average 8.9 medicines at
baseline)
Sixteen studies in hospital
settings, three in hospital
outpatient clinics, one at
the hospital/homecare
interface, 12 in an
inpatient setting, 10 in
primary care and six in
nursing homes
Thirty-one studies examined
complex, multifaceted
interventions of
pharmaceutical care in a
variety of settings
One unifaceted study
examined computerised
decision support provided
to GPs in their own
practices
Assessments using the
Cochrane Risk of bias tool
found that there was a
high and/or unclear risk
of bias across a number
of domains
Based on the GRADE
approach, the overall
certainty of evidence for
each pooled outcome
ranged from low to very
low
Redmond
et al [17]
N = 13 585 records after
duplicates removed
(25 RCTs in total,
22 included in the
meta-analyses)
Twenty-five RCTs involving
6995 participants
The mean age of
participants was
66.1 years
Most studies recruited
participants prescribed
multiple medications
All of the studies were
conducted in hospital or
immediately related
settings
All studied interventions
were classified as
“organisational”’
according to EPOC
taxonomy and were
either provider orientated
or structural
Twenty-three studies were
provider orientated
(pharmacist mediated)
and two were structural
(an electronic
reconciliation tool and
medical record changes)
There were no major
differences in the risk of
bias of studies included in
the review, with
24 studies being judged
at high risk for at least
one risk of bias domain
The GRADE evidence varied
from moderate to low or
very low reliability
Data extraction on the results of the systematic reviews (outcomes)
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Data extraction on the results of the systematic reviews (outcomes)
Study Outcomes: mortality Outcomes: adverse drug effects Outcomes: health, quality of life, resources
Outcomes: evidence on the number of
medicines
Jokanovic et al
[12]
Not an outcome Polypharmacy associated with an increased
risk of hospitalisation (adjusted for
confounders, n = 1), ADRs over 1 year
follow-up (unadjusted, n = 1) and falls
over a period of 6 months (unadjusted,
n = 1); the association with increased risk
of falls was diminished in the adjusted
analysis
Mean number of medications ranged from
3.8 to 16.6 per resident; median ranged
from 4 to 14
Prevalence of polypharmacy varied by
definition: 80-88% on 4+ medicines
(n = 2), 38-91% on 56 (n = 11), 46-69%
on 6+ (n = 3), 19-47% on 7+ (n = 2),
13-75% on 9+ (n = 13), 11-65% on 10+
(n = 11), 4-50% on 12+ (n = 2)
Polypharmacy was significantly associated
with higher Charlson comorbidity index
scores (n = 2), circulatory diseases
(n = 3), endocrine and metabolic
disorders (n = 3), neurological motor
dysfunctioning (n = 3) and some specific
symptoms (n = 2), recent discharge from
hospital (n = 2) and greater number of
prescribers servicing the LTCF (n = 2)
Inverse association with age (n = 5)
cognitive impairment (n = 3), disability in
activities of daily living (n = 3) and length
of stay in the LTCF (n = 3)
Leelakanok
et al [14]
MA of discrete polypharmacy: 1 additional
medicine has a risk ratio of 1.08
[1.04;1.12], I-squared = 54%
Polypharmacy as 1-4 medicines, risk
ratio = 1.24 [1.10; 1.39], I-squared = 78%
Polypharmacy as 5+ medicines, risk
ratio = 1.31 [1.17; 1.47] I-squared = 97%
Polypharmacy as 6-9 medicines, risk
ratio = 1.59 [1.36; 1.87], I-squared = 39%
Polypharmacy as 10+ medicines, risk
ratio = 1.96 [1.42; 2.71], I-squared = 99%
Results consistent across healthcare setting
in studies examining polypharmacy as
discrete number of medicines or as <10
medicines, but higher association in
people in institutions (although small
sample size)
Results consistent across different
measures of risk
Not an outcome Not an outcome Not an outcome
(Continues)
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Study Outcomes: mortality Outcomes: adverse drug effects Outcomes: health, quality of life, resources
Outcomes: evidence on the number of
medicines
Clyne et al [8] Not an outcome One study found no significant effect on
adverse drug effects from a pharmacist
intervention
Three pharmacist intervention studies
found no significant effect on
psychosocial outcome of quality of life
with SF-36, one study found a significant
decrease in the SF-36 domains of
emotional role and social functioning,
which was attributed to the high
withdrawal rate of pharmacists in the
study, one multifaceted intervention had
no significant effect on psychological
health (12-item well-being questionnaire)
Health service use was assessed in two
studies, with one reporting a reduction in
hospitalisations but not in A&E visits
Two studies conducted economic
evaluations: one study found that shared
pharmaceutical care and written
feedback had modest savings regarding
medication costs (not statistically
significant), and data analysis is ongoing
in the second study
The primary outcome was medication
appropriateness
Four of six organizational interventions
reported a reduction in PIP, particularly
through pharmacists conducting
medication reviews (three of four
studies on pharmacists interventions)
Evidence of the effectiveness of
multidisciplinary teams was weak
Both of the two professional (targeting
prescriber's directly) interventions were
computerised clinical decision support
interventions and were effective in
decreasing new PIP but not existing PIP
Three of four multifaceted approaches
were effective in reducing PIP
Hill-Taylor
et al [9, 10]
2013: In one study (Gallagher 2011)
all-cause mortality was lower in the
intervention group, but differences were
not statistically significant (5.3% of the
intervention group and 7.3% of the
control group died, P = 0 414)
2016: One RCT (Gallagher 2011) was not
powered to discover mortality
differences between groups
2013: The STOPP criteria identified more
medications associated with adverse drug
events than the 2002 version of the
Beers criteria
Patients with PIP, as identified by STOPP,
had an 85% increased risk of adverse
drug events in one study (Hamilton 2011)
(OR = 1 85, 95% CI: 1 51-2 26; P < 0
001)
2016: Not reported
2013: Research involving the application of
STOPP/START on the impact on the
quality of life was not found
2016: One RCT (Frankenthal 2014) did not
report a difference in quality of life
Resource use: One study found lower
primary care visits in the intervention
group
2013: There was limited evidence that the
application of STOPP/START criteria
optimised prescribing. Three studies
examined the direct costs of PIP in the
Republic of Ireland: €188 per patient per
year in 2007 (Barry et al40), €318 per
patient per year in 2007 (Cahir et al42)
and €263 per patient per year (Byrne
et al49)
Predictors of PIP were reported in nine
studies older age, female sex,
polypharmacy, comorbidities
2016: Improvement in potentially
inappropriate medication rates after
intervention, four RCTs, OR 2.98
(random effects; 95% CI 1.30, 6.83;
I-squared = 86.7%; three RCTs
(excluding outlier Gallagher 2011), OR
1.98 (random effects; 95% CI 1.16, 3.40;
I-squared = 64.3%)
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Study Outcomes: mortality Outcomes: adverse drug effects Outcomes: health, quality of life, resources
Outcomes: evidence on the number of
medicines
Johansson
et al [11]
The strategies to reduce polypharmacy had
no effect on all-cause mortality (all
studies: odds ratio 1.02; 95% CI 0.84,
1.23; RCTs only: OR 1.05, 95% CI 0.85,
1.29)
I-squared values for statistical
heterogeneity were 8% for all studies and
12% for just RCTs
None of the included studies analysed the
effect on new morbidity, ADR, adverse
events after discontinuation of drugs or
process of care
Overall, the effects of interventions on the
predefined secondary outcomes were
minimal
Hospitalisations: 11/25 studies reported
hospitalisation as an outcome measure,
two studies found a significant effect of
the intervention on hospitalisation, one
study found a reduction in the unplanned
readmission and the other found a
reduction in the length of stay, five
studies assessed all-cause hospital
admissions and found no significant
differences
Twenty-three studies provided data on the
number of prescribed drugs and two
studies included prescribed and
over-the-counter drugs
The weighted mean number of drugs at
baseline was 7.4 drugs per patient in
both groups; at follow-up, the weighted
mean number of drugs was reduced by
0.2 in the intervention group but
increased by 0.2 in the control groups; it
was not possible to calculate confidence
interval
Three studies found significant reduction
in a between-group analysis
Kua et al [13] Across 26 RCTs (12 248 residents)
deprescribing reduced mortality rates
(fixed effect: odds ratio 0.90, 95% CI
0.82, 0.99)
However, in the subgroup analysis by
intervention type, only medication
review-directed deprescribing
interventions (fixed effect: eight RCTs,
6 115 residents) was statistically
significant (OR 0.74, 95% CI 0.65, 0.84)
When a random-effects model was applied,
statistically significant differences were
not evident (all interventions, OR 1.02
95% CI 0.85, 1.23; medication review,
OR 0.83 95% CI 0.64, 1.07)
I-squared values for statistical
heterogeneity were 51% for all
interventions and 48% for medication
review
Subgroup analysis performed by the
authors found that studies conducted in
Australia found greater beneficial effects
(OR = 0.66, 95% CI 0.5-0.77) as well as
deprescribing by multiple drug classes
(OR = 0.89, 95% CI 0.81-0.98)
Fourteen studies examined drug
discontinuation by doctors, two studies
by pharmacists and one study by nurses;
86% of studies targeted psychotropic
drugs
Generally, the careful discontinuation of
antipsychotics and diuretics had
negligible adverse effects on psychiatric
and cardiovascular outcomes,
respectively
Ten studies (n = 6905 people) examined the
number of people who fell after the
intervention, with most reporting no
difference with the exception of one
study
Pooling of eight analysable studies
(n = 3343 people) suggested that
deprescribing interventions did not
significantly reduce the number of people
who had falls, with a significant result in
the subgroup analysis by medication
review-directed (OR = 0.76, 95% CI
0.62-0.93)
Eight studies (7863 residents) examined
hospitalisation rates after the
intervention, and most found no
difference; meta-analysis of four
analisable studies (n = 1002) found a
nonsignificant reduction in the number of
hospitalised residents (OR = 0.72, 95% CI
0.31-1.66)
Five studies (2092 people) reported PIMS
after the intervention period, according
to various criteria
All studies found a significant reduction in
PIMs; the meta-analysed OR for the
odds of people having PIMS was 0.41
(95% CI 0.19-0.89) from three
analysable studies (1711 people)
Page et al [15] Polypharmacy as deprescribing target:
10 RCTs (3151 patients): OR = 0.82
(0.61; 1.11); I-squared = 23%; educational
Single studies on polypharmacy,
glucosamine, carbamazepine,
antidepressants, benzodiazepine,
Large number of outcomes, largely
disease-specific
Deprescribing polypharmacy reduced the
total number of medicines (MD = –0.99
[−0.93; −0.14]) in two studies and the
(Continues)
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Study Outcomes: mortality Outcomes: adverse drug effects Outcomes: health, quality of life, resources
Outcomes: evidence on the number of
medicines
programmes have a OR = 1.21 (0.86;
1.69) whereas investigator led has
OR = 0.62 (0.43; 0.88); subgroup analysis
by age had similar results, aged 80+
OR = 0.88 (0.58; 1.34) (as per forest plot),
aged 65-79 years OR = 0.64 (0.40; 1.04);
similar results by presence of dementia
(0.89 [0.63; 1.27] with vs 0.64 [0.36;
1.13] without)
Nonrandomised studies on mortality
(OR = 0.32 [0.17; 0.60], N = 2)
Studies on deprescribing single/classes
medicines did not find a stats significant
difference on mortality odds
Beta-blockers (N = 1 RCT; OR = 1.14 [0.35;
3.72]), diuretics (N = 2 RCT, OR = 3.21
[0.96; 10.70]), statins (N = 1 RCT,
OR = 0.87 [0.58; 1.31]), bisphophonates
(N = 2 RCT, OR = 1.02 [0.46; 2.26]),
carbamazepine (N = 1 RCT, OR = 0.28
[0.01; 7.33]), antidepressants (N = 2 RCT,
OR = 1.13 [0.47; 2.69]), antipsychotics
(N = 5 RCT, OR = 0.59 [0.33; 1.07]),
benzodiazepines (N = 1 RCT, OR = 0.10
[0.01; 1.93]), anticholinesterease
inhibitors (N = 2 RCT, OR = 4.63 [0.93;
23.12]), ICS (N = 1 RCT, OR = 0.14 [0.01;
2.67]).
prednisolone, ICS); three studies on
antipsychotics
Heterogeneous results
The authors note that neither deprescribing
to reduce polypharmacy nor
deprescribing targeting single medicines
were not associated with a significant risk
in adverse drug withdrawal events
Quality of life assessed with a variety of
measures, including (but not restricted to)
EQ-5D utility and SF-36
The authors noted that in respect to
deprescribing of polypharmacy, there was
no change in the incidence of adverse
drug events, in cognitive function or the
risk of falls; there was a statistically
significant reduction in the number of
falls (MD = –0.11 [−0.21; −0.02];
844 participants; three studies)
The authors noted that deprescribing to
reduce polypharmacy was not associated
with significant changes in quality of life,
although there was evidence of a
reduction in the decline in quality of life
(MD = 0.03 [0.01; 0.06], 189 patients,
one study)
In respect to deprescribing of single
medicines, there were some changes in
relevant outcomes, specifically increase
in blood pressure when antihypertensive
drugs were prescribed (eg, increase in
9.73 mm Hg in systolic blood pressure
with deprescribing of diuretics)
number of PIMs (MD = –0.49 [−0.70;
0.28]) in three studies
Inconsistent effect depending on the type
of class/medicine
Rankin et al
[16]
Not an outcome Medication-related problems were reported
in eight studies (N = 10 087) using
different terms (eg, adverse drug
reactions, drug-drug interactions)
No consistent intervention effect on
medication-related problems was noted
across studies
In one study participants in the intervention
group experienced an increased QoL, in
one study there was a decline in QoL in
both the intervention and control groups,
and in 10 studies no changes in QoL
were detected
Pharmaceutical care may make little or no
difference in hospital admissions (two
studies)
It is uncertain whether pharmaceutical
care improves medication
appropriateness (as measured by an
implicit tool) (MD -4.76, 95% CI -9.20 to
−0.33), reduces the number of PIMs
(SMD –0.22, 95% CI –0.38 to −0.05),
reduces the proportion of patients with
one or more PIMs (RR 0.79, 95% CI
0.61-1.02), reduces the proportion of
patients with one or more PPOs
(RR 0.40, 95% CI 0.18-0.85)
Pharmaceutical care may slightly reduce
the number of PPOs (SMD −0.81, 95%
CI –0.98 to −0.64 (two studies)
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Study Outcomes: mortality Outcomes: adverse drug effects Outcomes: health, quality of life, resources
Outcomes: evidence on the number of
medicines
Redmond et al
[17]
One study reported no difference in
mortality (RR 0.75, 95% CI 0.27-2.08)
One study reported potential ADEs;
defined as being due to discrepancies,
three studies described an outcome of
PADEs or ameliorable ADEs calculated
using the bates methodology to
retrospectively identify
medication-related ADEs with no
certainty of whether reconciliation
reduced PADEs or nonadherence, four
studies reported reconciliation may make
little or no difference to ADEs (RR 1.09,
95% CI 0.91-1.30; I-squared = o%)
Reconciliation also had little or no effect on
PADEs (RR 0.37. 95% CI 0.09-1.57; three
studies; I-squared = 84%) or on ADEs
(RR 1.09, 95% CI 0.91-1.30; four studies;
I-squared = 0%)
Evidence of the effect of the interventions
on healthcare utilisation was conflicting
and had an uncertain effect on a
composite measure of hospital utilisation
(emergency department, rehospitalisation
RR 0.78, 95% CI 0.50-1.22; four studies;
I-squared = 48%)
Twenty studies comparing medication
reconciliation interventions to standard
care of participants with at least one
medication discrepancy showed RR 0.53
(95% CI 0.42-0.67; I-squared = 91%)
Reconciliation's effect on the number of
reported discrepancies per participant
was also uncertain (MD –1.18, 95% CI –
2.58-0.23; four studies;
I-squared = 96%), as well as its effect on
the number of medication discrepancies
per participant medication (RR 0.13,
95% CI 0.01-1.29; two studies;
I-squared = 98%)
aA&E, ; ADEs, adverse drug events; ADR, CI, EPOC, GRADE, ICS, LTCF, MAI, MD, mean difference; PADES, preventable adverse drug events; PIMs, potentially inappropriate medications; PIP, PPOs, potential
prescribing omissions; QoL, RCT, RR, ; SMD, standardised mean difference.
bData extraction on the conclusions of the included systematic reviews
Data extraction on the conclusions of the included systematic reviews
Study Conclusions of the systematic review Limitations as reported by the authors Areas for future research suggested by the authors
Jokanovic et al [12] The prevalence of polypharmacy in residents in LTCFs
is high, but varies widely between LTCFs and
depending on the definition of polypharmacy. The
factors positively associated with polypharmacy are
comorbidity, recent hospital discharge, number of
prescribers; inversely associated are older age,
cognitive impairment, ADL disability and length of
stay in LTCF.
Not all relevant studies may have been picked up by
the searches due to restrictions due to language
(English) and date (year 2000+). Clinical
appropriateness was not assessed in this review. No
meta-analysis performed, which was due to the
heterogeneity in the included studies.
Future studies should use consistent definitions of
polypharmacy, have a longitudinal design and collect
information on factors that may influence the
exposure to polypharmacy and health outcomes.
Leelakanok et al [14] Polypharmacy is associated with higher mortality risk,
and relationship is dose-dependent (higher mortality
risk for more medicines).
Risk of exposure misclassification in the included
studies, given that some studies did not provide
detailed information on the medicines and/or
collected information from self-report or surveys.
Risk of confounding bias in that the association
between polypharmacy and mortality may not be
causal. Focus on mortality, when drugs may be
prescribed to improve QoL with known increased
risk of mortality (eg, opioids in palliative care).
Heterogeneity in the definition of polypharmacy.
Not discussed.
(Continues)
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Study Conclusions of the systematic review Limitations as reported by the authors Areas for future research suggested by the authors
Exclusion of studies due to lack of data to calculate a
risk ratio for the association.
Clyne et al [8] Interventions including organisational (pharmacist
interventions), professional (computerized clinical
decision support systems) and multifaceted
approaches appear beneficial in terms of reducing
PIP, but the range of effect sizes reported was
modest, and it is unclear whether such interventions
can result in clinically significant improvements in
patient outcomes.
Meta-analysis could not be undertaken due to
heterogeneity, few studies conducted process
evaluations or presented adequate detail to allow for
an analysis, studies did not describe usual care in
adequate detail, potential biases limited studies,
particularly in relation to selection bias and only half
of the studies had adequate sample size.
Although the interventions appear to have been
beneficial in terms of reducing PIP, the clinical effect
this may have on outcomes such as ADEs and QoL is
unknown. Future research should consider involving
individuals to explore their preferences in relation to
PIP and interventions to decrease it and explore
whether the differences in decreasing the initiation
of PIP, as opposed to the discontinuation of existing
PIP, results from differences in the interventions or
differences in applying explicit or implicit criteria.
Hill-Taylor et al [9, 10] 2013: The STOPP/START criteria appear to be more
sensitive than the 2002 version of the beers criteria.
Limited evidence was found related to the clinical
and economic impact of the STOPP/START criteria
2016: STOPP/START may be effective in improving
prescribing quality, clinical, humanistic and economic
outcomes.
2013: Although referred to as “STOPP” or “START”,
some researchers used versions of the criteria that
had been modified for their jurisdictional prescribing
practices or formularies and in some instances were
shortened. Not all researchers had access to
complete medication profiles including
over-the-counter medications. No study indicated an
attempt to document or evaluate adherence.
Researchers who had used pharmacy claims data
were only able to confirm that patients had made a
claim for medications, not that they have actually
taken them
2016: Three of the studies had populations that were
restricted to a single facility and interventions
performed in the included studies varied in
implementation, populations, outcomes and
duration.
2013: To date, the clinical, humanistic and economic
impacts of the application of the STOPP/START
criteria have not been well explored
2016: Additional research investigating STOPP/START
is needed, especially in frail elderly and
community-living patients receiving primary care.
Johansson et al [11] There is no convincing evidence that the strategies
assessed are effective in reducing polypharmacy or
have an impact on clinically relevant endpoints.
The quality of the evidence assessed using GRADE on
strategies to reduce polypharmacy was rated as low
to very low, and any estimate of effect is very
uncertain. There was insufficient evidence on the
effect of strategies to reduce polypharmacy on
patient relevant outcomes such as mortality and
hospitalisation.
There is a need to develop more effective strategies to
reduce inappropriate polypharmacy and to test them
in large, pragmatic randomised controlled trials on
effectiveness and feasibility. When addressing
polypharmacy, research groups should clearly define
their methodology regarding the assessment of
medication appropriateness, and they should also
focus on clinically relevant outcomes such as
mortality or hospital admissions.
Kua et al [13] Compared to other deprescribing interventions,
medication review directed deprescribing had
significant benefits on older residents in nursing
homes.
There was limited evidence to show that deprescribing
was effective in reducing all-cause mortality, number
of fallers, as well as hospitalization rates. However,
when the deprescribing activity involved a
medication review by healthcare professionals in a
Further studies are needed to fully ascertain the health
benefits of medication reviewed directed
deprescribing practice.
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Study Conclusions of the systematic review Limitations as reported by the authors Areas for future research suggested by the authors
structured and active way, it significantly reduced
both all-cause mortality and number of fallers,
compared to other types of deprescribing
interventions.
Page et al [15] Deprescribing appears to be feasible and safe. There is
no evidence of an increased risk of adverse
outcomes and some evidence of greater likelihood
of positive health outcomes. Overall, RCTs found no
effect of deprescribing interventions had on
mortality risk, although patient-specific interventions
in particular had a significant reduction on mortality
risk. Health outcomes varied by target medication
for withdrawal and include a reduction in the
number of falls and increase in blood pressure.
Deprescribing is feasible. Concluded that
deprescribing should be routinely considered for
older people.
Language bias, inclusion of nonrandomised studies and
small RCTs with low quality, inclusion of studies that
aimed to assess the feasibility of deprescribing
intervention, heterogeneity in follow-up, settings
and patients' characteristics.
Large RCTs on patient-specific deprescribing
interventions to confirm the findings of the review.
Research to understand which medications should
be prescribed in whom and at what point in time.
Rankin et al [16] It is unclear whether interventions to improve
appropriate polypharmacy, such as reviews of
patients' prescriptions, resulted in clinically
significant improvement, but they may be slightly
beneficial in terms of reducing PPOs, but this effect
estimate is based on only two studies, which had
serious limitations in terms of risk bias.
The meta-analysis based on the number of PPOs per
participant comprised just two studies. This limits
the value of any pooled effect estimate. Based on
observed heterogeneity in the pooled effect
estimates, the findings of meta-analyses (medication
appropriateness as measured by an implicit tool), the
number of PIMs and proportion of patients with one
or more PIMs or PPOs should be treated cautiously,
as the interventions did not seem to work
consistently across all studies. Furthermore, the
certainty of evidence presented in this review, as
described by the GRADE approach, remains low or
very low.
Further research should attend to rigour in study
design. More research is needed to test whether
existing tools for comprehensive medication review
can improve appropriate polypharmacy.
Redmond et al [17] The impact of medication reconciliation interventions,
in particular pharmacist-mediated interventions, on
medication discrepancies is uncertain due to the
certainty of the evidence being very low. There was
also no certainty of the effect of the interventions
on the secondary clinical outcomes of ADEs, PADEs
and healthcare utilisation.
Meta-analysis of the primary outcomes showed a high
degree of statistical heterogeneity and low certainty
of evidence, making it difficult to have any certainty
of the effect of the interventions.
Further work is required to develop a consensus on
identifying, defining, measuring and reporting
discrepancies. Future studies should utilise clear
definitions of discrepancies as well as objective
measurement techniques and appropriate choice of
time points attendant to the transition point at
which the intervention is applied.
aADR, adverse drug reaction; CI, confidence interval; EPOC, Effective Practice and Organisation of Care; GRADE, Grading of Recommendations Assessment, Development and Evaluation; ICS, inhaled corticoste-
roids; LTCF, long-term care facility; MAI, Medicines Appropriateness Index; MD, mean difference.
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Study (to reorder once referenced) Reason for exclusion
Clyne et al56 Did not meet quality assessment criteria for inclusion
Gutierrez Valencia et al57 Did not meet quality assessment criteria for inclusion
Tani et al58 Did not meet quality assessment criteria for inclusion
Thillainadesan et al59 Did not meet quality assessment criteria for inclusion
Tija et al60 Did not meet quality assessment criteria for inclusion
Disalvo et al61 Not a topic of interest
Palmer et al62 Not a topic of interest
Patton et al63 Not a topic of interest
Piraino et al64 Not a topic of interest
Stewart et al65 Not a question of interest
Thompson et al66 Not a question of interest
Ulley et al67 Not a question of interest
APPENDIX 3: STUDIES EXCLUDED AT THE FULL-TEXT STAGE WITH REASON
AMSTAR-2 quality assessment judgements for exclusion (“yes” required for all domains for inclusion)
Study Topic
Comprehensive search
strategy
Duplicate data
extraction
Quality
assessment
Study
description
Clyne et al56 Effectiveness of interventions to
reduce PP
Yes Cannot tell Cannot tell Yes
Gutierrez Valencia
et al57
Effectiveness of interventions to
reduce PP
Yes Yes Cannot tell Yes
Tani et al58 Effectiveness of interventions to
reduce PP
Yes Cannot tell No Yes
Thillainadesan
et al59
Effectiveness of interventions to
reduce PP
Yes No Yes Yes
Tija et al60 Effectiveness of interventions to
reduce PP
Yes Yes No Yes
aPP, problematic polypharmacy.
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